Objective To update the 2016 formal consensus-based guidance for the management of
myasthenia gravis (MG) based on the latest evidence in the literature. Methods In October …

The complement system plays a key role in pathogen immunosurveillance and tissue
homeostasis. However, subversion of its tight regulatory control can fuel a vicious cycle of …

Background There is an unmet need for treatment options for generalised myasthenia gravis
that are effective, targeted, well tolerated, and can be used in a broad population of patients …

Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating
autoimmune disease. New treatments for this disease are needed because conventional …

Background Generalised myasthenia gravis is a chronic, unpredictable, and debilitating rare
disease, often accompanied by high treatment burden and with an unmet need for more …

Background Generalized myasthenia gravis (gMG) is a rare, chronic, and debilitating
autoimmune disease. Activation of the complement system by autoantibodies against the …

Background Chimeric antigen receptor (CAR) T cells are highly effective in treating
haematological malignancies, but associated toxicities and the need for lymphodepletion …

Ravulizumab, a new complement component C5 inhibitor administered every 8 weeks, was
noninferior to eculizumab administered every 2 weeks in complement-inhibitor–naive …

Background Complement pathway inhibition may provide benefit for severe acute
respiratory illnesses caused by viral infections such as COVID-19. We present results from a …

Myasthenia gravis (MG) is a chronic, fluctuating, antibody-mediated autoimmune disorder
directed against the post-synaptic neuromuscular junctions of skeletal muscles, resulting in …